"Meaningful progress has been made this year as we streamlined our product candidate portfolio to focus on our most promising asset. We believe Landos is uniquely positioned to transform the treatment paradigm for patients with ulcerative colitis with our novel, oral, once-daily treatment NX-13," said Gregory Oakes, President and CEO of Landos. "Our capital efficient approach focuses resources towards advancing the clinical development of NX-13, while maximizing our ability to create value for our shareholders."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LABP:
